Janux Therapeutics (NASDAQ:JANX) Now Covered by Analysts at Leerink Partners

Leerink Partners started coverage on shares of Janux Therapeutics (NASDAQ:JANX) in a report released on Friday, Marketbeat.com reports. The firm issued an outperform rating and a $79.00 price target on the stock.

Other equities analysts have also recently issued reports about the stock. William Blair reaffirmed an “outperform” rating on shares of Janux Therapeutics in a report on Thursday, November 14th. Stifel Nicolaus started coverage on shares of Janux Therapeutics in a research note on Friday, September 6th. They issued a “buy” rating and a $70.00 price objective on the stock. UBS Group started coverage on shares of Janux Therapeutics in a research note on Thursday, October 24th. They set a “buy” rating and a $69.00 target price for the company. HC Wainwright reissued a “buy” rating and set a $63.00 price target on shares of Janux Therapeutics in a report on Thursday, November 7th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $100.00 price objective on shares of Janux Therapeutics in a research note on Thursday, November 7th. One investment analyst has rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $67.70.

Janux Therapeutics Stock Performance

JANX opened at $48.82 on Friday. Janux Therapeutics has a one year low of $7.79 and a one year high of $65.60. The stock has a market capitalization of $2.56 billion, a P/E ratio of -41.73 and a beta of 3.52. The business’s 50-day simple moving average is $50.05 and its 200-day simple moving average is $45.83.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.18). Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. The firm had revenue of $0.44 million for the quarter, compared to analysts’ expectations of $1.50 million. The business’s revenue was down 82.6% on a year-over-year basis. On average, equities research analysts forecast that Janux Therapeutics will post -1.34 EPS for the current fiscal year.

Insider Activity

In other Janux Therapeutics news, major shareholder Ventures Xi L.P. Avalon sold 108,365 shares of the business’s stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $42.00, for a total transaction of $4,551,330.00. Following the completion of the sale, the insider now directly owns 3,162,851 shares in the company, valued at $132,839,742. The trade was a 3.31 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO David Alan Campbell sold 25,000 shares of the stock in a transaction dated Monday, October 28th. The shares were sold at an average price of $53.54, for a total value of $1,338,500.00. Following the completion of the sale, the chief executive officer now owns 282,054 shares of the company’s stock, valued at approximately $15,101,171.16. This trade represents a 8.14 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 420,610 shares of company stock valued at $19,288,666 in the last 90 days. 29.40% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Janux Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. Summit Securities Group LLC acquired a new stake in shares of Janux Therapeutics in the second quarter valued at approximately $29,000. Amalgamated Bank raised its position in shares of Janux Therapeutics by 61.1% during the second quarter. Amalgamated Bank now owns 970 shares of the company’s stock worth $41,000 after purchasing an additional 368 shares during the period. Plato Investment Management Ltd purchased a new stake in Janux Therapeutics during the second quarter valued at about $42,000. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Janux Therapeutics by 21.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock valued at $87,000 after acquiring an additional 339 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Janux Therapeutics in the second quarter worth $151,000. Institutional investors and hedge funds own 75.39% of the company’s stock.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.